In This Section


Please note that this meeting will take place as an in-person event in Austin and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

[R] – Remote Presentation
* – Short talk from proffered abstract

Monday, January 23, 2023

Welcome and Keynote Lectures

Tuesday, January 24, 2023

Plenary Session 1: Apoptosis
Plenary Session 2: Stem Cells
Plenary Session 3: Epigenetics
Plenary Session 4: Niche/Microenvironment
Plenary Session 5: Splicing Mutations

Wednesday, January 25, 2023

Plenary Session 6: Minimal Residual Disease
Plenary Session 7: Inflammation
Plenary Session 8: Cell and Immune Targeting in Myeloid Malignancies

Monday, January 23, 2023

Welcome and keynote lectures
5-6:30 p.m.   

Understanding and targeting altered RNA splicing in myeloid malignancies
Omar Abdel-Wahab, Memorial Sloan Kettering Cancer Center, New York, New York 

Germline predisposition to myeloid malignancies
Lucy A. Godley, University of Chicago, Chicago, Illinois

Opening Reception  
6:45-8:30 p.m.  

Tuesday, january 24, 2023

Continental Breakfast 
7-8 a.m. 
Plenary Session 1: Apoptosis
Session Chair: Courtney D. DiNardo, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-9:35 a.m. 

Inducing apoptosis in leukemia stem cells by targeting metabolism
Courtney L. Jones, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Understanding and preventing resistance to BCL2 inhibitor therapy in AML
Courtney D. DiNardo

Understanding differential addiction to anti-apoptotic BCL-2 family towards developing novel treatments in hematological malignancies
Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, Michigan

Panel Discussion

9:35-9:55 a.m.
Plenary Session 2: STEM CELLS
Session Chair: Ravi Majeti, Stanford University, Stanford, CAlifornia
9:55-11:45 a.m.

Approaches to targeting leukemia stem cells
Monica L. Guzman, Weill Cornell Medicine, New York, New York 

Mapping the cellular origins of pediatric leukemia
Eric R. Lechman, UPMC Hillman Cancer Center, Pittsburgh, PA

Stem cells in human AML
Ravi Majeti

Novel anti-leukemia activity of the IRE1-XBP1 signaling pathway in hematopoietic stem and progenitor cells*
Stanley Adoro, National Cancer Institute, Bethesda, Maryland

Panel Discussion

11:45-12:00 P.m.
Plenary Session 3: Epigenetics 
Session Chair: Maria (Ken) Figueroa, University of Miami, Miami, Florida 
12:00 P.m.-1:30 p.m.

Epigenomic landscapes of MDS
Maria (Ken) Figueroa

Enhancing TET function for the treatment of myeloid malignancies
Luisa Cimmino, University of Miami Miller School of Medicine, Miami, Florida 

Targeting IDH-mutant myeloid leukemia by disabling metabolic dependencies
Jian Xu, UT Southwestern Medical Center, Dallas, Texas 

Panel Discussion

Lunch on own/free time
1:30-3:15 p.m.
Session Chair: Iannis Aifantis, NYU Langone Health, New York, New York
3:15-5:15 p.m.

Dissecting the cross-talk between normal, leukaemic stem cells, and the bone marrow microenvironment [R]
Dominique Bonnet, The Francis Crick Institute, London, England

MSCs boost AML bioenergetics and facilitate escape from chemotherapy [R]
Simón Méndez-Ferrer, University of Cambridge, Cambridge, England

Anatomy of normal and leukemic hematopoiesis in the bone marrow
Daniel Lucas, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

Interactions with the immune microenvironment in MDS and AML
Iannis Aifantis

Panel Discussion

5:15-5:30 p.m.
Plenary Session 5:  Splicing Mutations
Session chair: Esther A. Obeng, St. Jude Children’s Research Hospital, Memphis, Tennessee 
5:30-7:05 p.m.

Therapeutic targeting of the Rbm39 splicing factor in immunity
Sydney X. Lu, Memorial Sloan Kettering Cancer Center, New York, New York 

Targeting SF3B1 in myelodysplastic syndromes
Esther A. Obeng

Genetic determinants of clonal expansion rate in pre-malignant HSCs
Siddhartha Jaiswal, Stanford University, Stanford, California

Panel Discussion  

Poster Session/Reception
7:15-9:30 p.m.

Wednesday, January 25, 2022

Continental Breakfast
7-8 a.m.
Plenary Session 6: Measurable Residual Disease
Session Chair: Christopher S. Hourigan, National Heart, Lung and Blood Institute, Bethesda, Maryland
8-9:35 a.m.

Measurable residual disease in AML: A roadmap for evidence and implementation
Christopher S. Hourigan

Measurable residual disease assessment for lower intensity therapy in AML
Farhad Ravandi-Kashani, The University of Texas MD Anderson, Houston, Texas 

Targeting senescence-like resilient AML cells to reduce measurable/minimal residual disease
Cihangir Duy, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Panel Discussion

9:35-9:55 a.m.
Plenary Session 7: Inflammation
 Session Chair: Ruben A. Mesa, Mays Cancer Center at UT Health San Antonio, San Antonio, Texas
9:55-11:45 a.m. 

Inflammation and the MPNs: From phenotype to therapy
Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

Age- and gut injury-induced accumulation of a bacterial metabolite promotes expansion of leukemic cells
Daniel T. Starczynowski, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

Fish and CHIPs: Dissecting the mechanisms of clonal disorders using cellular barcoding
Serine Avagyan, University of California, San Francisco, CA

RSK1 targeting impedes oncogenic driver and inflammatory cytokine signaling to attenuate myeloid neoplasms*
Tim Kong, Washington University in St. Louis School of Medicine, St. Louis, Missouri

Panel Discussion

11:45-12:00 P.m.
Plenary Session 8: Cell and Immune Targeting in Myeloid Malignancies
Session Chair: Paresh Vyas, University of Oxford, Oxford, United Kingdom 
12:00 P.m.–1:45 p.m. 

Graft versus Leukemia (GvL): Identification and characterization of alloreactive antigens and cognate T cell responses in acute myeloid leukemia
Paresh Vyas

ADCLEC.syn1 CAR T cells detect combinatorial target signatures to safely prevent antigen-low AML escape*
Sascha Haubner, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion 

Closing remarks
1:25 p.m. 

Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC